openPR Logo
Press release

Tyrosine Kinase Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030

08-29-2023 05:54 PM CET | Health & Medicine

Press release from: Orion Market Research

Tyrosine Kinase Market Share, Trends, Future Outlook, Analysis

The global tyrosine kinase market is anticipated to witness a considerable CAGR of during the forecast period. The rising prevalence of cancer across the globe along with the growing R&D of new tyrosine kinase inhibitors is a key factor anticipated to drive the growth of the global tyrosine kinase market. According to the World Health Organization (WHO), cancer is the second leading cause of mortality across the globe which is responsible for around 9.6 million mortalities and accounted for 18.1 million new cases in 2018, globally. 1 in 5 men and 1 in 6 women, across the globe, develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease.

A full report of Tyrosine Kinase Market is available at: https://www.omrglobal.com/industry-reports/tyrosine-kinase-market

The tyrosine kinase inhibitors are given to the patients in order to stop the growth of cancer cells. Therefore, the high prevalence of different kinds of cancers is anticipated to create the demand for these drugs, which in turn is driving the growth of the tyrosine kinase inhibitor drugs across the globe.

GlaxoSmithKline PLC, Novartis International AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eurofarma Laboratórios S/A, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, and so on are the key companies operating in the tyrosine kinase market across the globe. The major players of the tyrosine kinase market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global tyrosine kinase market.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/tyrosine-kinase-market

Recent Development in the Market

In May 2018, Pfizer, Inc. had announced the US Food and Drug Administration (FDA) approval for the breakthrough therapy designation for XALKORI (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. In addition, the FDA had granted breakthrough therapy designation for XALKORI for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.

Global Tyrosine Kinase Market Segmentation

By Type

BCR-ABL Tyrosine Kinase Inhibitor
Epidermal Growth Factor Receptor (EGFR)
Vascular Endothelial Growth Factor Receptor (VEGFR)
Anaplastic Lymphoma Kinase (ALK)
Others

By Application

Chronic Myeloid Leukemia (CML)
Lung Cancer
Breast Cancer
Renal Cell Cancer
Other

Tyrosine Kinase Market- Segment by Region

North America

United States
Canada

Europe

Germany
United Kingdom
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

Middle East & Africa
Latin America

Company Profiles

ARIAD Pharmaceuticals, Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Eurofarma Laboratórios S/A
Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Johnson and Johnson
Merck & Co., Inc.
Novartis AG

Reasons to Buying From us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Kinase Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030 here

News-ID: 3187251 • Views:

More Releases from Orion Market Research

Antiviral Drug Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Antiviral Drug Market Size, Trends, Latest Insights, Analysis and Forecast 2024- …
The global antiviral drugs market is estimated to witness significant growth during the forecast period. Increasing viral infections such as Human immune deficiency virus (HIV), influenza A & B, hepatitis B & C are the major driving factor of the global antiviral drug market. There have been considerable advances in the innovation as well as the demand for HIV drugs. According to UN India, Pakistan and China are among the
Anti-snoring Treatment Market is Dazzling Worldwide and Forecast to 2031
Anti-snoring Treatment Market is Dazzling Worldwide and Forecast to 2031
Anti-snoring treatment market is expected to witness positive growth during the forecast period. Snoring is a common condition occurs in anyone, more frequently in men and people who are overweight. Snoring not only disrupt the sleep patterns of others, but also weaker sleep quality of the person. Snoring has the tendency to rise due to increasing age. The habitual snoring can be a sign of serious health problems and obstructive
Anti-Hypertensive Drugs Market is Dazzling Worldwide and Forecast to 2031
Anti-Hypertensive Drugs Market is Dazzling Worldwide and Forecast to 2031
The global anti-hypertension drugs market is estimated to grow at a CAGR of over 4% during the forecast period. Hypertension is a common condition among patients with diabetes. Hence, the adoption of anti-hypertensive is high among the diabetic population for the treatment of hypertension. Hence, the increased diabetic population coupled with the adoption of anti-hypertensive drugs is anticipated to drive the anti-hypertensive drug market industry significantly. Additionally, Angiotensin-converting enzyme (ACE)
Antidepressant Drugs Market is Dazzling Worldwide and Forecast to 2031
Antidepressant Drugs Market is Dazzling Worldwide and Forecast to 2031
The global antidepressant drug market is expected to grow at a significant CAGR during the forecast period. Antidepressants are used for the treatment of all age group patients suffering from clinical and anxiety depression and are further used for regulating mood. As per the Centers for Disease Control and Prevention (CDC), during the period, 2011-2014, 12.7% of people aged 12 and overtook antidepressant medication. This, in turn, reflects the increasing

All 5 Releases


More Releases for Kinase

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market Manufacturers …
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market Research 2018 A market study "Global Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market" examines the performance of the Dual Specificity Mitogen Activated Protein Kinase Kinase 2 market 2018. It encloses an in-depth Research of the Dual Specificity Mitogen Activated Protein Kinase Kinase 2 market state and the competitive landscape Globally. This report analyzes the potential of Dual Specificity Mitogen Activated
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK …
ReportsWorldwide has announced the addition of a new report title Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Tyrosine Protein Kinase CSK - Pipeline Review, H2 2017'; Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or
MAP Kinase Interacting SerineThreonine Protein Kinase 1 (MAP Kinase Signal Integ …
ReportsWorldwide has announced the addition of a new report title MAP Kinase Interacting SerineThreonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (SerineThreonine K …
ReportsWorldwide has announced the addition of a new report title Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (SerineThreonine Kinase MNB or MNBDYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or
Aurora Kinase A (Aurora 2 or SerineThreonine Protein Kinase 15 or SerineThreonin …
ReportsWorldwide has announced the addition of a new report title Aurora Kinase A (Aurora 2 or SerineThreonine Protein Kinase 15 or SerineThreonine Protein Kinase 6 or SerineThreonine Protein Kinase Aurora A or AuroraIPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Aurora Kinase A - Pipeline Review, H2 2017'; Aurora Kinase
MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Inte …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “MAP Kinase Interacting Serine/Threonine Protein Kinase 1 - Pipeline Review, H2 2017”, constitutes close to 7 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report MAP Kinase Interacting SerineThreonine Protein Kinase 1 - Pipeline Review, H2 2017, outlays comprehensive information on